Plasma asymmetric dimethylarginine and cardiovascular events in patients with acute decompensated heart failure (Q40075348)

17 September 2017

Plasma asymmetric dimethylarginine and cardiovascular events in patients with acute decompensated heart failure (English)

1 reference

Acute decompensated heart failure

17 September 2017

0 references

1 reference

5

Michael Wolzt

1 reference

17 September 2017

Christina Dückelmann

1

1 reference

17 September 2017

Friedrich Mittermayer

series ordinal

2

1 reference

17 September 2017

Dominik G Haider

series ordinal

3

1 reference

17 September 2017

Johann Altenberger

series ordinal

4

1 reference

17 September 2017

2 June 2008

1 reference

17 September 2017

Translational Research

1 reference

17 September 2017

152

1 reference

17 September 2017

1

1 reference

17 September 2017

24-30

1 reference

The problem of decompensated heart failure: nomenclature, classification, and risk stratification

17 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.05.001

The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.05.001

Comparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.05.001

A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.05.001

Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.05.001

Guidelines for the diagnosis and treatment of chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.05.001

Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.05.001

Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.05.001

Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.05.001

Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.05.001

Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.05.001

Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.05.001

Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.05.001

Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.05.001

Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.05.001

Asymmetric dimethylarginine enhances cardiovascular risk prediction in patients with chronic heart failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.05.001

Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.05.001

Acute Escherichia coli endotoxaemia decreases the plasma l-arginine/asymmetrical dimethylarginine ratio in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.05.001

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.05.001

NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.05.001

High plasma level of asymmetric dimethylarginine in patients with acutely exacerbated congestive heart failure: role in reduction of plasma nitric oxide level

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.05.001

Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.05.001

Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.05.001

Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.05.001

Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.05.001

Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.05.001

Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.05.001

Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.05.001

Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.05.001

Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.05.001

Relation between gender, etiology and survival in patients with symptomatic heart failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2008.05.001

10.1016/J.TRSL.2008.05.001

7 January 2021

Identifiers

DOI

1 reference

17 September 2017

1 reference